MRGPRX2

Across TCGA pan-cancer cohorts, MRGPRX2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MRGPRX2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MRGPRX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRGPRX2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, BLCA, and BRCA are the cancer types where MRGPRX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.074	0.703	<.001	48	view →
BLCA	DFS	Median	All	0.166	0.625	.020	15	view →
BRCA	OS	Median	All	0.162	0.924	<.001	12	view →
SKCM	OS	Median	II,III,IV	0.762	0.298	.016	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MRGPRX2–ESCA (OS)

Open the ESCA breakdown →